Anand Odedra1,2, Kari Mudie3, Glen Kennedy3, Rebecca E Watts4, Emilie Rossignol4, Hayley Mitchell4, Jeremy Gower4, Maria Rebelo4, Zuleima Pava4, Rebecca Pawliw4, Stephen Woolley4,5, David G Lalloo5, Greg Robinson4, Sean Lynch4, Katharine A Collins4,6, Fiona Amante4, James McCarthy4. 1. QIMR Berghofer Medical Research Institute, Herston Road, Brisbane, QLD, 4006, Australia. anand_tony@hotmail.co.uk. 2. Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK. anand_tony@hotmail.co.uk. 3. Haematology Department, Royal Brisbane and Women's Hospital, Butterfield Street, Herston, Brisbane, QLD, 4029, Australia. 4. QIMR Berghofer Medical Research Institute, Herston Road, Brisbane, QLD, 4006, Australia. 5. Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK. 6. Department of Medical Microbiology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.
Abstract
BACKGROUND: In the absence of a method to culture Plasmodium vivax, the only way to source parasites is ex vivo. This hampers many aspects of P. vivax research. This study aimed to assess the safety of apheresis, a method for selective removal of specific components of blood as a means of extracting and concentrating P. vivax parasites. METHODS: An iterative approach was employed across four non-immune healthy human subjects in single subject cohorts. All four subjects were inoculated with ~ 564 blood stage P. vivax (HMP013-Pv) and subjected to apheresis 10 to 11 days later. Blood samples collected during apheresis (haematocrit layers 0.5% to 11%) were tested for the presence and concentration of P. vivax by microscopy, flow cytometry, 18S rDNA qPCR for total parasites, and pvs25 qRT-PCR for female gametocyte transcripts. Safety was determined by monitoring adverse events. Malaria transmission to mosquitoes was assessed by membrane feeding assays. RESULTS: There were no serious adverse events and no significant safety concerns. Apheresis concentrated asexual parasites by up to 4.9-fold (range: 0.9-4.9-fold) and gametocytes by up to 1.45-fold (range: 0.38-1.45-fold) compared to pre-apheresis densities. No single haematocrit layer contained > 40% of all the recovered P. vivax asexual parasites. Ex vivo concentration of parasites by Percoll gradient centrifugation of whole blood achieved greater concentration of gametocytes than apheresis. Mosquito transmission was enhanced by up to fivefold in a single apheresis sample compared to pre-apheresis. CONCLUSION: The modest level of parasite concentration suggests that the use of apheresis may not be an ideal method for harvesting P. vivax. Trial Registration Australia New Zealand Clinical Trials Registry (ANZCTR) Trial ID: ACTRN12617001502325 registered on 19th October 2017. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373812.
BACKGROUND: In the absence of a method to culture Plasmodium vivax, the only way to source parasites is ex vivo. This hampers many aspects of P. vivax research. This study aimed to assess the safety of apheresis, a method for selective removal of specific components of blood as a means of extracting and concentrating P. vivax parasites. METHODS: An iterative approach was employed across four non-immune healthy human subjects in single subject cohorts. All four subjects were inoculated with ~ 564 blood stage P. vivax (HMP013-Pv) and subjected to apheresis 10 to 11 days later. Blood samples collected during apheresis (haematocrit layers 0.5% to 11%) were tested for the presence and concentration of P. vivax by microscopy, flow cytometry, 18S rDNA qPCR for total parasites, and pvs25 qRT-PCR for female gametocyte transcripts. Safety was determined by monitoring adverse events. Malaria transmission to mosquitoes was assessed by membrane feeding assays. RESULTS: There were no serious adverse events and no significant safety concerns. Apheresis concentrated asexual parasites by up to 4.9-fold (range: 0.9-4.9-fold) and gametocytes by up to 1.45-fold (range: 0.38-1.45-fold) compared to pre-apheresis densities. No single haematocrit layer contained > 40% of all the recovered P. vivax asexual parasites. Ex vivo concentration of parasites by Percoll gradient centrifugation of whole blood achieved greater concentration of gametocytes than apheresis. Mosquito transmission was enhanced by up to fivefold in a single apheresis sample compared to pre-apheresis. CONCLUSION: The modest level of parasite concentration suggests that the use of apheresis may not be an ideal method for harvesting P. vivax. Trial Registration Australia New Zealand Clinical Trials Registry (ANZCTR) Trial ID: ACTRN12617001502325 registered on 19th October 2017. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373812.
Authors: Q Cheng; G Lawrence; C Reed; A Stowers; L Ranford-Cartwright; A Creasey; R Carter; A Saul Journal: Am J Trop Med Hyg Date: 1997-10 Impact factor: 2.345
Authors: James S McCarthy; Paul M Griffin; Silvana Sekuloski; A Taylor Bright; Rebecca Rockett; David Looke; Suzanne Elliott; David Whiley; Theo Sloots; Elizabeth A Winzeler; Katharine R Trenholme Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Arjen M Dondorp; Caterina I Fanello; Ilse C E Hendriksen; Ermelinda Gomes; Amir Seni; Kajal D Chhaganlal; Kalifa Bojang; Rasaq Olaosebikan; Nkechinyere Anunobi; Kathryn Maitland; Esther Kivaya; Tsiri Agbenyega; Samuel Blay Nguah; Jennifer Evans; Samwel Gesase; Catherine Kahabuka; George Mtove; Behzad Nadjm; Jacqueline Deen; Juliet Mwanga-Amumpaire; Margaret Nansumba; Corine Karema; Noella Umulisa; Aline Uwimana; Olugbenga A Mokuolu; Olanrewaju T Adedoyin; Wahab B R Johnson; Antoinette K Tshefu; Marie A Onyamboko; Tharisara Sakulthaew; Wirichada Pan Ngum; Kamolrat Silamut; Kasia Stepniewska; Charles J Woodrow; Delia Bethell; Bridget Wills; Martina Oneko; Tim E Peto; Lorenz von Seidlein; Nicholas P J Day; Nicholas J White Journal: Lancet Date: 2010-11-07 Impact factor: 79.321
Authors: Rebecca J Rockett; Sarah J Tozer; Chris Peatey; Seweryn Bialasiewicz; David M Whiley; Michael D Nissen; Katharine Trenholme; James S Mc Carthy; Theo P Sloots Journal: Malar J Date: 2011-02-28 Impact factor: 2.979
Authors: Stephen D Woolley; Louise Marquart; John Woodford; Stephan Chalon; Joerg J Moehrle; James S McCarthy; Bridget E Barber Journal: Malar J Date: 2021-12-20 Impact factor: 2.979
Authors: Angela M Minassian; Yrene Themistocleous; Sarah E Silk; Jordan R Barrett; Alison Kemp; Doris Quinkert; Carolyn M Nielsen; Nick J Edwards; Thomas A Rawlinson; Fernando Ramos Lopez; Wanlapa Roobsoong; Katherine Jd Ellis; Jee-Sun Cho; Eerik Aunin; Thomas D Otto; Adam J Reid; Florian A Bach; Geneviève Mc Labbé; Ian D Poulton; Arianna Marini; Marija Zaric; Margaux Mulatier; Raquel Lopez Ramon; Megan Baker; Celia H Mitton; Jason C Sousa; Nattawan Rachaphaew; Chalermpon Kumpitak; Nongnuj Maneechai; Chayanut Suansomjit; Tianrat Piteekan; Mimi M Hou; Baktash Khozoee; Kirsty McHugh; David J Roberts; Alison M Lawrie; Andrew M Blagborough; Fay L Nugent; Iona J Taylor; Kimberly J Johnson; Philip J Spence; Jetsumon Sattabongkot; Sumi Biswas; Julian C Rayner; Simon J Draper Journal: JCI Insight Date: 2021-12-08